Ovarian cancer is the fifth leading cause of cancer death among women in the United States and the most lethal gynecologic malignancy, with approximately 19,000…
Medically reviewed by MedCentralHub Medical Review Board, Licensed Pharmacists & Physicians ·
Ovarian cancer is the fifth leading cause of cancer death among women in the United States and the most lethal gynecologic malignancy, with approximately 19,000 new cases and 13,000 deaths annually in the US. It is often called the 'silent killer' because 70–75% of cases are diagnosed at advanced stages (III–IV) due to vague early symptoms and lack of effective screening. High-grade serous ovarian carcinoma (HGSOC) is the most common histologic subtype (70%). Landmark advances include PARP inhibitor maintenance therapy and BRCA-targeted treatment, which have extended progression-free survival in BRCA1/2-mutated and HRD-positive disease.
This information is for educational purposes only. Always consult a qualified healthcare professional for diagnosis and personalized treatment.
Abdominal bloating or swelling (most common complaint)
Pelvic or abdominal pain
Difficulty eating or feeling full quickly
Urinary urgency or frequency
Fatigue, back pain, constipation (less specific)
Ascites causing visible abdominal distension
Palpable pelvic/abdominal mass on exam
Menstrual irregularities or postmenopausal bleeding (less common)
Pleural effusion causing dyspnea in advanced disease
Pelvic exam — adnexal mass
Transvaginal ultrasound (TVUS) — first-line imaging; assess morphology, vascularity
CT abdomen/pelvis with contrast — staging, peritoneal implants, lymphadenopathy, ascites
MRI pelvis — tissue characterization of complex adnexal masses
PET-CT — recurrence evaluation
Serum CA-125 — elevated in >80% of HGSOC; not useful for screening but valuable for monitoring
HE4 (human epididymis protein 4) — combined with CA-125 in ROMA score for risk stratification
Surgical staging (laparotomy/laparoscopy): definitive diagnosis, histologic classification, FIGO staging
BRCA1/2 germline and somatic testing (all patients); HRD testing (BRCAness) for PARP inhibitor selection
Carboplatin + Paclitaxel
Standard first-line chemotherapy. Carboplatin AUC 5-6 + Paclitaxel 175 mg/m² every 3 weeks x 6 cycles. IV or IP (intraperitoneal) delivery for optimal-debulking candidates.
Bevacizumab (Avastin)
Anti-VEGF. Added to carboplatin/paclitaxel and continued as maintenance for stage III/IV. GOG-0218 and ICON7 trials. Greatest benefit in high-risk (stage IV, residual disease).
PARP Inhibitors (Olaparib, Niraparib, Rucaparib)
Maintenance therapy after complete or partial response to first-line platinum-based chemotherapy. Olaparib (Lynparza) for BRCA1/2-mutated; niraparib for all-comers. SOLO-1, PRIMA, VELIA trials.
Olaparib + Bevacizumab Maintenance
PAOLA-1 trial: olaparib + bevacizumab maintenance for HRD-positive (BRCAm or HRD+) disease. 5.5-year improvement in median PFS in BRCA-mutated patients.
Gemcitabine + Carboplatin (Relapsed Platinum-Sensitive)
For platinum-sensitive relapse (>6 months from last platinum). AGO-OVAR 2.5 trial. Often combined with bevacizumab.
Genetic counseling and BRCA1/2 testing for all patients and at-risk first-degree relatives
Risk-reducing bilateral salpingo-oophorectomy (RRSO) recommended for BRCA1 carriers (ages 35–40) and BRCA2 carriers (ages 40–45) after childbearing complete
Oral contraceptives: 5 years of use reduces lifetime ovarian cancer risk by ~50% (also reduces endometrial cancer risk)
Maintain healthy weight (BMI <30)
Avoid talcum powder use in genital area (potential risk factor — evidence mixed)
Breastfeeding and parity are protective
Peritoneal/ascites symptoms: low-sodium diet, gentle ambulation, paracentesis if severe
Survivorship care: sexual health counseling, menopause management, osteoporosis prevention (after RRSO)
Prognosis
5-year relative survival: Stage I: 90–95%; Stage II: 70–80%; Stage III: 25–40%; Stage IV: <15%. BRCA1/2-mutated HGSOC has paradoxically better response to platinum and PARP inhibitors vs. BRCA wild-type. PARP inhibitor maintenance has extended median PFS from ~14 months to >36 months in BRCA-mutated advanced ovarian cancer. Recurrence after first-line therapy remains common (>70% at 5 years), and the goal in most advanced cases is disease control with good quality of life rather than cure.
Ovarian Cancer is a medical condition classified under Oncology. Ovarian cancer is the fifth leading cause of cancer death among women in the United States and the most lethal gynecologic malignancy, with approximately 19,000 new cases and 13,000 deaths annually in the US. It is often called the 'silent killer' because 70–75% of cases are diagnosed at advanced stages (III–IV) due to vague early symptoms and lack of effective screening. Understanding Ovarian Cancer is essential for patients, families, and healthcare providers to ensure timely diagnosis, appropriate treatment, and optimal outcomes.
Last reviewed by MedCentralHub Medical Review Board · MedCentralHub Editorial Policy
Medical Disclaimer
The information on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult your doctor or a qualified healthcare provider with any questions about a medical condition.